Sofosbuvir (Sovaldi)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Sofosbuvir

What it is

Sofosbuvir is a direct-acting antiviral for hepatitis C: a nucleotide that the virus's NS5B polymerase builds into its RNA, stopping the chain. Combined with other antivirals (as in Harvoni, Epclusa and Vosevi) it cures most hepatitis C infections in 8 to 12 weeks. It is sold as Sovaldi.

How genes come into it

Sofosbuvir is a prodrug activated inside liver cells by CES1, HINT1 and other enzymes, and studies have looked at variants in these genes for its levels. Others looked at the IFNL3/IFNL4 region, which strongly predicted cure with older interferon treatment; with sofosbuvir-based medicines its effect is small. There is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Sofosbuvir. Upload your DNA file to see which of these rows apply to you.

Rated evidence (6 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

IFNL3;IFNL4 rs12979860: Level 3. Efficacy: Chronic hepatitis C virus infection. 2.

IFNL4 rs11322783: Level 3. Efficacy: Chronic hepatitis C virus infection. 1.

IFNL3;IFNL4 rs12979860: Level 3. Efficacy: Chronic hepatitis C virus infection. 1.

IFNL3;IFNL4 rs12979860: Level 3. Efficacy: Chronic hepatitis C virus infection, Recurrence. 1.

Response (9 findings)

Studies of how well it worked in people carrying a variant.

CES1 rs4513095: Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.

HINT1 rs7728773: Genotypes CT + TT is associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotype CC.

IFNL3 rs12979860: Genotype CC is associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.

IFNL3, IFNL4 rs12979860: Genotype CC is associated with increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to genotypes CT + TT.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Deleobuvir (NS5B Inhibitors)

Actemra (IL-6 Inhibitors)

Agenerase (Protease Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com